Page last updated: 2024-08-25

3-deazaneplanocin and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one

3-deazaneplanocin has been researched along with 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cui, B; Guan, H; Hou, P; Ji, M; Shi, B; Yang, Q	1

Other Studies

1 other study(ies) available for 3-deazaneplanocin and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one

Article	Year
PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:6 Topics: Adenosine; Animals; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice; Mice, Nude; Mutant Proteins; Thyroid Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2014

Article

Year

PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.

The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:6

Topics: Adenosine; Animals; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice; Mice, Nude; Mutant Proteins; Thyroid Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2014